Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 14, 2021 4:59pm
159 Views
Post# 33208291

RE:AIGH Capital Management new stake reported

RE:AIGH Capital Management new stake reported

They seem to be overweight on biotech/pharma.

So Leah et al got 4 institutions onboard, from what you say here in advance of, but likely expecting, an offering. Is that a good return for 12 months work? Presumably these guys are being chased by 100's of small biotech.


SPCEO1 wrote: AIGH, a small money manager out of Baltimore, added nearly 3 million shares in Q1 to the roughly 570,000 it bought in last year's fourth quarter. I imagine most, if not all, the newly acquired shares came via the OO. They now own 3.8% of the total shares outstanding and are the third largest shareholder according to Bloomberg's data after Soleus and my firm. But I also know that Bloomberg's data does not capture all the shareholder groups accurately, so they are really more likey the sixth largest shareholder.

Unlike Soleus, I don't think AIGH brings anything extra to t he TH party. They apparently are just a smart money manager who knows a bargain when they see one.

 

<< Previous
Bullboard Posts
Next >>